Prostate MRI

Multiparametric prostate MRI at 3 Tesla, combining T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences to detect, localise, and grade prostate lesions according to PI-RADS criteria. The 3T field strength provides the signal-to-noise ratio needed for reliable diffusion imaging of the prostate gland.

Multiparametric prostate MRI (mpMRI) has become the standard-of-care investigation for men with elevated PSA levels or clinical suspicion of prostate cancer. The examination at Medicover Hospital uses the 3T Magnetom 3 Neo, which provides the field strength recommended by the European Society of Urogenital Radiology for prostate imaging — 3T delivers superior spatial and contrast resolution compared to 1.5T systems, improving the detection of clinically significant cancers (Gleason grade group 2 or higher). The multiparametric protocol combines three complementary sequences: T2-weighted imaging for anatomical detail and zonal architecture; diffusion-weighted imaging (DWI) with ADC mapping to identify areas of restricted water movement characteristic of dense tumour cellularity; and dynamic contrast-enhanced (DCE) imaging to evaluate tumour vascularity. Findings are reported using the PI-RADS v2.1 scoring system, which standardises the probability of clinically significant cancer on a 1-5 scale. Medicover's urology department has particular depth in prostate pathology, including the hospital's patented SMART prostatectomy technique performed using the da Vinci Xi robotic system. This means mpMRI findings can be directly correlated with the surgical team when biopsy or intervention is indicated. The hospital holds European Section of Robotic Urology (ERUS) recognition for its prostate surgery outcomes.